Foldax Presents at the 2021 Transcatheter Valve Technologies Meeting
July 29, 2021
Last week, Foldax presented on the company’s innovative Tria valve at the 2021 Transcatheter Valve Technologies (TVT) meeting. View the slides HERE.
The presentation titled “Foldax Biopolymer Valves: An Alternative to Tissue Based Leaflet Valves” was given by Foldax investigator, Dr. David Heimansohn, chief of surgery at St. Vincent/Ascension in Indiana and was well received. During his talk he detailed the Tria technology and the excellent hemodynamic results from its US Aortic Surgical Early Feasibility Study (EFS).
The aortic EFS is the first in a series of clinical studies Foldax will be conducting on its Tria LifePolymer heart valve line.
Tria™ heart valves are made with revolutionary new LifePolymer™ material and designed to last a lifetime. Our goal is to help millions of patients with aortic, mitral, and tricuspid valve disease receive cost-effective treatment in a single heart valve procedure.
“The Q&A session following the presentation showed a lot of interest in Tria LifePolymer valves as the wave of the future,” said Mike Numamoto, vice president of marketing for Foldax.
Recent News
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
